Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964637 | 0.81 | ADORA1 (0.36) | ADORA1 | |
| SCHEMBL5552998 | 0.77 | ADORA1 (0.34) | ADORA1 | |
| SCHEMBL17375471 | 0.77 | ADORA1 (0.34) | ADORA1 | |
| SCHEMBL31211432 | 0.75 | NOS3 (0.32) | — | |
| SCHEMBL18263952 | 0.75 | TTK (0.32) | ADORA1 | |
| SCHEMBL23571797 | 0.75 | HPGD (0.33) | — | |
| SCHEMBL12138525 | 0.74 | ADORA1 (0.33) | ADORA1 | |
| SCHEMBL24529479 | 0.74 | HTR2C (0.47) | — | |
| SCHEMBL24164067 | 0.73 | ADORA1 (0.34) | ADORA1 | |
| SCHEMBL25416250 | 0.72 | TGFBR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| CN-118786117-A | Heterocyclic amides and methods of use thereof | 亚根达医疗公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4433457-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023092098-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3160967-B1 | N-(IMIDAZO[1,2-A]PYRAZIN-6-YL)-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-9975900-B2 | Substituted imidazo[1,2-α]pyrazines for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975900-B2 | Substituted imidazo[1,2-α]pyrazines for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975900-B2 | Substituted imidazo[1,2-α]pyrazines for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3160967-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015197503-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015197503-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | SNRPA, SF3B5, RBM17 | ADORA1 2886/4885 |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PYGM, GYS1 | ADORA1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.